Tesamorelin: Growth Hormone Benefits

What Is Tesamorelin?

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. Developed by Theratechnologies, it received FDA approval in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Tesamorelin holds a unique position in the peptide world as one of the few GH-related peptides with full FDA approval and extensive human clinical data. While its approved indication is specific to HIV-related lipodystrophy, its mechanism of action -- stimulating natural growth hormone release -- has applications that extend well beyond this population.

Mechanism of Action

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and release of growth hormone. Unlike exogenous GH (which suppresses the HPG axis through negative feedback), tesamorelin works within the natural regulatory framework. The body's normal feedback mechanisms remain intact, including somatostatin-mediated GH pulse regulation and IGF-1 negative feedback at the hypothalamic level.

This means tesamorelin produces physiologically normal GH pulses rather than the supraphysiological, continuous elevation seen with exogenous GH injection. The result is more natural GH signaling with a lower risk of the side effects associated with high-dose GH therapy.

Clinical Evidence

Visceral Fat Reduction

The approval trials for tesamorelin involved over 800 HIV-positive patients with excess visceral adipose tissue. Key findings from these trials included an average 18% reduction in visceral adipose tissue (VAT) at 26 weeks (measured by CT scan), preserved subcutaneous fat (tesamorelin selectively targets visceral fat), improved triglyceride levels, and maintained lean body mass.

The selective targeting of visceral fat is clinically significant because visceral adipose tissue is the most metabolically dangerous fat depot, strongly associated with cardiovascular disease, insulin resistance, and systemic inflammation.

Cognitive Function

An intriguing secondary finding from tesamorelin research involves cognitive effects. A study published in Archives of Neurology examined tesamorelin in older adults with mild cognitive impairment (MCI) or healthy cognition. After 20 weeks, tesamorelin-treated subjects showed improved executive function (Trail Making Test B), better verbal memory performance, and increased cerebrospinal fluid concentrations of amyloid-beta (suggesting improved amyloid clearance). These cognitive findings have generated interest in GH-mediated neuroprotection and are being further investigated.

Liver Fat and NAFLD

Clinical studies have shown tesamorelin reduces hepatic fat content. A 12-month trial in HIV patients with NAFLD demonstrated a 37% reduction in liver fat (measured by MRI), prevention of fibrosis progression, and improved liver enzyme levels. Given the growing epidemic of NAFLD/NASH in the general population, these findings have significant potential relevance beyond the HIV population.

Dosing and Administration

• FDA-approved dose: 2 mg subcutaneous injection once daily
• Injection site: Abdomen (rotate sites within the abdominal area)
• Timing: Same time each day (morning preferred by most users)
• Duration: Clinical benefits are maintained with continuous use; fat regain occurs within 12 weeks of discontinuation

Peptide Calculator Settings

Tesamorelin research vials vary in size. Using the Peptide Calculator Plus with a typical setup:

• 2 mg vial + 2 mL BAC water = 1 mg/mL
• For 2 mg dose: draw 100 units on a U-100 syringe (full 1 mL syringe = one dose from the vial)
• With this reconstitution, one 2 mg vial provides exactly one dose

Side Effects

Tesamorelin was generally well-tolerated in clinical trials. The most common adverse effects were injection site reactions (erythema, pruritus, pain, irritation) in up to 30% of patients. Other reported effects include arthralgia (joint pain, 13%), peripheral edema (6%), myalgia (5%), and carpal tunnel syndrome-like symptoms (rare). These GH-related side effects are generally milder than those seen with exogenous GH therapy, likely because tesamorelin produces physiological rather than supraphysiological GH levels.

Tesamorelin vs CJC-1295 vs Exogenous GH

All three increase GH levels but through different mechanisms. Tesamorelin is FDA-approved with extensive safety data, preserves pulsatile GH release, and selectively reduces visceral fat. CJC-1295 (no DAC) is a shorter-acting GHRH analog often paired with Ipamorelin, with less human data but widely used in research. Exogenous GH directly provides GH (bypassing the pituitary), produces the highest GH levels, but has the most side effects and suppresses endogenous GH production.